AZAixia Zhang

Aixia Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aixia Zhang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Downregulation of hepatoma-derived growth factor suppresses the malignant phenotype of U87 human glioma cells

    by Aixia Zhang, Weiguo Long, Ze Guo, Zhenying Guo, Brian B. Cao

    Hepatoma-derived growth factor (HDGF) has been shown to correlate with increased malignancy of different types of tumors and could be an independent prognostic index for human cancers. We previously found that HDGF is overexpressed in glioma tissues and that its expression level may correlate with the clinical pathological grade. In the present study, we investigated the effects of HDGF downregulation on the biological behaviors of U87 glioma cells. Our results showed that HDGF knockdown significantly inhibited the malignant phenotype of U87 cells, including the colony formation, migration and invasion in vitro, as well as tumorigenesis in vivo. Our data also suggest that hepatocyte growth factor/scatter factor (HGF/SF) may contribute to the HDGF-associated aggressive behavior of glioma cells.


  • Open Access

    Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA

    by Zhang Aixia, Cao Brian

    Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellular carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent assay (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recombinant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blotting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).


  • Open Access

    Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells

    by Chongfeng Gao, Zhenying Guo, Yuanzheng He, Shuangshuang Wang, Aixia Zhang, Ping Zhao, Brian Cao

    Hepatoma-derived growth factor (HDGF) has been implicated in the growth and metastasis of various types of human cancer, but the role of HDGF expression in prostate cancer or breast cancer has not been documented. To assess the role of HDGF in the proliferation, migration and invasion by prostate and breast cancer cells, HDGF expression in DU145 and MCF7 cells was knocked down using siRNA, and the effect of such knockdown was assessed by MTS and [3H]-thymidine incorporation Transwell assays. Moreover, we identified differentially expressed genes that might mediate the HDGF-induced cellular effects. Our results demonstrate that down-regulation of HDGF expression significantly reduces the proliferation of both DU145 and MCF7 cells. However, down-regulation of HDGF expression in DU145 inhibited cell migration and invasion, but in MCF7 cells it stimulated cell migration and invasion. This differential effect might result from the differential induction of PIK3R1 or SERPINE1 in the two cell lines upon HDGF-siRNA treatment. In conclusion, HDGF may participate in the pathogenesis of prostate and breast cancer by promoting cell growth and it may be a therapeutic target for these cancers.


    • 1 October 2009
      • Vol. 29  (10) , 4005-11

    Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts.

    by Ning Xu, Gangming Cai, Wanzhong Ye, Xin Wang, Yunqian Li, Ping Zhao, Aixia Zhang, Rongjun Zhang, Brian Cao

    Suitable diagnostics could identify patients who might benefit from targeted therapies. Molecular imaging is a promising method estimating the expression of specific molecules in vivo, and the goal of this study was to evaluate a radioiodinated anti-epidermal growth factor receptor (EGFR) human Fab as a molecular imaging agent for diagnosis. Three human tumor cell lines representing tumors with different levels of EGFR expression were selected and their corresponding xenografts produced. (125)I was conjugated to a human anti-EGFR Fab that recognizes the native extracellular domain of EGFR evidenced by immunoprecipitation (IP) and fluorescence-activated cell sorting (FACS) assays. Single-photon-emission computed tomography (SPECT) imaging of (125)I-Fab being administered to nude mice bearing xenografts were obtained, and further analyzed by region of interest (ROI) assay. The (125)I-Fab was achieved successfully without losing its immunoreactivity. The scintigrams as well as ROI assay showed that (125)I-Fab was able to clearly quantitatively distinguish the different expression levels of EGFR in vivo. (125)I-Fab is a potential molecular imaging agent for clinical diagnosis of EGFR-overexpressing tumors.